Publications (36) Publications de María Elena Díaz Rodríguez

2024

  1. Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma

    Cancer Cell International, Vol. 24, Núm. 1

  2. Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer

    Nutrients, Vol. 16, Núm. 15

  3. Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer

    Oncogenesis, Vol. 13, Núm. 1

  4. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2022

  1. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

  2. Antitumoral properties of the nutritional supplement ocoxin oral solution: A comprehensive review

    Nutrients, Vol. 12, Núm. 9, pp. 1-18

2019

  1. Central role of cell cycle regulation in the antitumoral action of ocoxin

    Nutrients, Vol. 11, Núm. 5

  2. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

    Cancer Letters, Vol. 453, pp. 34-44

2018

  1. Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer

    International Journal of Oncology, Vol. 53, Núm. 1, pp. 113-123

2017

  1. Antitumoral effect of ocoxin in hepatocellular carcinoma

    Oncology Letters, Vol. 14, Núm. 2, pp. 1950-1958

  2. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity

    Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651

  3. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

2016

  1. Antitumoral effect of Ocoxin on acute myeloid leukemia

    Oncotarget, Vol. 7, Núm. 5, pp. 6231-6242

  2. Modulation of cereblon levels by anti-myeloma agents

    Leukemia and Lymphoma, Vol. 57, Núm. 1, pp. 168-176

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

    Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516

  2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. A modular approach to trim cellular targets in anticancer drug discovery

    Bioorganic and Medicinal Chemistry Letters, Vol. 21, Núm. 22, pp. 6641-6645